Orgovyx Now Available for Advanced Prostate Cancer
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
Diagnosis & Disease Information
USPSTF Updates Guidelines for PSA-Based Screening for Prostate Cancer in Older Men
In updating its 2012 recommendations, the US Preventive Services Task Force changes its stance on PSA-based screening for prostate cancer in men older than 50. The new guidelines advocate for a patient-physician discussion of the benefits of testing vs the potential harms.
USPSTF: Decision to Undergo PSA Screening Should Be Individual
The decision to undergo periodic PSA screening for prostate cancer should be an individual one for men aged 55 to 69 years, according to the recommendation statement.
Challenges of Shared Decision Making in Prostate Cancer Screening
A review of shared decision making with men about undergoing PSA testing revealed that although full SDM discussions are increasing, variations in whether these discussions occur and how much information is shared still exist.
PSA Screening Increases Prostate Cancer Detection, No Significant Difference in Mortality
Researchers conducted a randomized clinical study of men to determine the impact of PSA screening on prostate cancer detection and mortality.
PSA Screening Rates Level Off in United States
Decline in prostate-specific antigen (PSA) screening followed U.S. Preventive Services Task Force recommendations.
Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
Abiraterone acetate and prednisone reduced PSA levels in a small group of clinical trial participants with metastatic prostate cancer who did not initially respond to ADT.
Disparities Growing in Prescreening Discussions About Prostate-Specific Antigen Testing
Conversations about benefits and drawbacks of PSA testing improved after the USPSTF updated its recommendations on PSA testing; however, some disparities in quality of these discussions increased.
Prostate Cancer Treatment Rates Decrease Following Changes in Treatment Recommendations
The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.
Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing
Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...